BioInvent International AB (STU:BIX) Cyclically Adjusted Revenue per Share: €0.34 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:BIX BioInvent International AB STU:BIX
51 GF Score
Price €2.04
GF Value €4.40
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB Cyclically Adjusted Revenue per Share?

BioInvent International AB STU:BIX -0.97% 51 Cyclically Adjusted Revenue per Share is €0.34 as of Mar. 2026. GuruFocus rates STU:BIX with a GF Score™ of 51/100 and a GF Value™ of €4.40 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BioInvent International AB's adjusted revenue per share for the three months ended in Mar. 2026 was €0.019. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.34 for the trailing ten years ended in Mar. 2026.

During the past 12 months, BioInvent International AB's average Cyclically Adjusted Revenue Growth Rate was -13.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -18.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -18.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of BioInvent International AB was -13.20% per year. The lowest was -22.30% per year. And the median was -18.15% per year.

As of today (2026-08-12), BioInvent International AB's current stock price is €2.035. BioInvent International AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.34. BioInvent International AB's Cyclically Adjusted PS Ratio of today is 5.99.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioInvent International AB was 11.53. The lowest was 1.57. And the median was 3.85.


BioInvent International AB  (STU:BIX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioInvent International AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.035/0.34
=5.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioInvent International AB was 11.53. The lowest was 1.57. And the median was 3.85.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BioInvent International AB Cyclically Adjusted Revenue per Share Related Terms


BioInvent International AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BioInvent International AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioInvent International AB Cyclically Adjusted Revenue per Share Chart

BioInvent International AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.74 0.69 0.48 0.37 0.39

BioInvent International AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.40 0.40 0.39 0.34

STU:BIX vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, BioInvent International AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Cyclically Adjusted PS Ratio falls into.


STU:BIX
51GF Score
BioInvent International AB STU:BIX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioInvent International AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioInvent International AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.019/133.5600*133.5600
=0.019

Current CPI (Mar. 2026) = 133.5600.

BioInvent International AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.100 101.019 0.132
201609 0.007 101.138 0.009
201612 0.287 102.022 0.376
201703 0.104 102.022 0.136
201706 0.097 102.752 0.126
201709 0.060 103.279 0.078
201712 0.111 103.793 0.143
201803 0.088 103.962 0.113
201806 0.065 104.875 0.083
201809 0.044 105.679 0.056
201812 0.070 105.912 0.088
201903 0.117 105.886 0.148
201906 0.162 106.742 0.203
201909 0.080 107.214 0.100
201912 0.118 107.766 0.146
202003 0.077 106.563 0.097
202006 0.076 107.498 0.094
202009 0.047 107.635 0.058
202012 0.246 108.296 0.303
202103 0.015 108.360 0.018
202106 0.009 108.928 0.011
202109 0.005 110.338 0.006
202112 0.008 112.486 0.009
202203 0.027 114.825 0.031
202206 0.436 118.384 0.492
202209 0.026 122.296 0.028
202212 0.029 126.365 0.031
202303 0.022 127.042 0.023
202306 0.017 129.407 0.018
202309 0.034 130.224 0.035
202312 0.021 131.912 0.021
202403 0.008 132.205 0.008
202406 0.006 132.716 0.006
202409 0.017 132.304 0.017
202412 0.028 132.987 0.028
202503 0.031 132.825 0.031
202506 0.274 133.699 0.274
202509 0.005 133.480 0.005
202512 0.004 133.390 0.004
202603 0.019 133.560 0.019

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.34 mean?
BioInvent International AB (STU:BIX) has a Cyclically Adjusted Revenue per Share of €0.34 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioInvent International AB and its competitors.
Is BioInvent International AB's Cyclically Adjusted Revenue per Share too high?
BioInvent International AB's current Cyclically Adjusted Revenue per Share is €0.34. Overall, BioInvent International AB has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
BioInvent International AB's Cyclically Adjusted Revenue per Share of €0.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioInvent International AB and its competitors. BioInvent International AB's current Cyclically Adjusted Revenue per Share is €0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
Based on GuruFocus' analysis, BioInvent International AB (STU:BIX) is currently considered Possible Value Trap. The stock's GF Value™ is €4.40, compared to a current price of €2.04 — trading 53.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.34. BioInvent International AB's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BioInvent International AB (STU:BIX), the current Cyclically Adjusted Revenue per Share is €0.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioInvent International AB (STU:BIX) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of €2.04 is trading 53.8% below its estimated GF Value™ of €4.40. GuruFocus considers BioInvent International AB to be Possible Value Trap.

Key valuation signals for STU:BIX:

  • Cyclically Adjusted Revenue per Share: €0.34
  • GF Value™: €4.40 vs. price of €2.04 (53.8% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the STU:BIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioInvent International AB Business Description

Other Exchanges BINV:Sweden0H22:UK
Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
51GF Score

Get the complete analysis for STU:BIX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.04
Price
€4.40
GF Value